简介内容:SIAIS117, a potent Brigatinib-PROTAC degrader, effectively degrades the ALK G1202R point mutation through its design based on Brigatinib and VHL-1 conjunction. It inhibits the proliferation of SR and H2228 cancer cell lines, demonstrating potential anti-proliferative effects against small cell lung cancer [1].